Clarus Ventures
Clarus Ventures is a Cambridge, Massachusetts-based life sciences venture capital firm, now operating as Blackstone Life Sciences (BXLS). It funds late-stage clinical development of innovative medicines through direct, enterprise-scale collaborations with pharmaceutical, biotechnology, and medical technology companies.
- Company typePrivate
- Founded2008
- HeadquartersCambridge, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Clarus Ventures does
Clarus Ventures is a Cambridge, Massachusetts-based venture capital and private equity firm founded in the mid-2000s that invests exclusively in the life sciences sector. The firm has since been acquired by Blackstone Inc. and now operates as Blackstone Life Sciences (BXLS), a dedicated development capital platform within one of the world's largest alternative asset managers. Clarus/BXLS collaborates directly with pharmaceutical, biotechnology, and medical technology companies to design, fund, and execute late-stage clinical trials for innovative medicines and technologies, targeting a reported 13 therapeutic areas with an 86% Phase 3 success rate (2010–2026).
The firm's core capability is hands-on clinical development underwriting rather than traditional venture equity. Its technology stack is centered on clinical trial design, funding, and execution expertise, delivered by a team of 20+ MDs and PhDs that is collectively credited with bringing 200+ medicines to market. Representative transactions include a $2 billion strategic collaboration with Alnylam anchored on a royalty interest in inclisiran (Leqvio), up to $750 million of development funding for Moderna's influenza mRNA vaccine program (March 2024), and the founding and subsequent sale of Anthos Therapeutics to Novartis.
Clarus/BXLS generates returns primarily through development investment returns and royalty interests in approved products, supplemented by a small equity component in selected counterparties. Revenue is therefore market- and interest-rate-uncorrelated in design, capturing value directly from funded products rather than from broader equity market exposure. Distribution is relationship-based and enterprise-only: the firm negotiates bespoke development capital agreements with pharma, biotech, and medtech counterparties, with no consumer-facing channels or disclosed standardized pricing.
Clarus Ventures firmographics
Firmographics- Name
- Clarus Ventures
- Legal name
- Clarus Ventures
- Website
- https://clarusfunds.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Acquired
- Headcount range
- 51–100 employees
- Short description
- Clarus Ventures is a Cambridge, Massachusetts-based life sciences venture capital firm, now operating as Blackstone Life Sciences (BXLS). It funds late-stage clinical development of innovative medicines through direct, enterprise-scale collaborations with pharmaceutical, biotechnology, and medical technology companies.
- Ownership category
- akta.pro rank
Clarus Ventures industry classification
Industry- Product category
- Life Sciences Private Equity
- NAICS
- Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394), Funds, Trusts, and Other Financial Vehicles (525), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Investment Advice (6282), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Business Services (B2B) Growth Equity (FSANACAD)
Keywords
Where Clarus Ventures is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Markets served
Clarus Ventures business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Others
Revenue model
- Development Investment Returns: Returns generated from funding late-stage clinical development of innovative pharmaceutical products. Returns are primarily market and interest rate uncorrelated, capturing value directly from products funded rather than from equity market exposure.
- Royalty Interests: Acquisition of royalty interests in approved products (e.g., Alnylam inclisiran/Leqvio). Generates returns through royalty payments on approved medicines.
- Equity Investments: A small percentage of deals include equity investments in counterparties. Some investments include equity kicker investments ancillary to primary investment.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Clarus Ventures product offering
Product offeringCore offering
Clarus Ventures, now operating as Blackstone Life Sciences (BXLS), is a life sciences-focused private equity firm that designs, funds and executes late-stage clinical trials for pharmaceutical, biotech and medical technology products. The firm provides development capital, royalty interest acquisitions, and operational expertise to advance innovative core products through clinical development and regulatory approval.
Product overview
Clarus Ventures, now operating as Blackstone Life Sciences (BXLS), is a private equity investment firm focused on life sciences. Rather than offering technology products, the firm provides investment capital and strategic collaboration services to pharmaceutical, biotech, and medical technology companies. The firm focuses on funding late-stage clinical development of innovative medicines and technologies, offering up to $750M in funding per collaboration (as demonstrated in the Moderna partnership). BXLS works with counterparties to jointly advance critical path products through hands-on involvement and operational expertise, targeting 13 different therapeutic areas with a 86% Phase 3 success rate.
Differentiator
Problem solved
Functional benefit
Products and services
- Late-Stage Clinical Development Funding Development capital for funding late-stage (Phase III) clinical trials of innovative pharmaceutical products from highly credible counterparties; includes hands-on involvement in clinical trial design and execution.
- Royalty Interest Acquisition
Quantifiable outcome
- 86% Phase 3 success rate (2010-2026)
- +2 more outcomes
Companies that use Clarus Ventures
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
Clarus Ventures technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Clarus Ventures partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- ModernacoreBlackstone Life Sciences announced collaboration to advance Moderna's influenza mRNA vaccine program. BXLS provides up to $750M of funding. This landmark transaction showcases the long-standing strategy to collaborate with leading life science companies to advance critical path products.
- AlnylamcoreBXLS led a $2 billion strategic collaboration anchored around the acquisition of a royalty interest in inclisiran (Leqvio). Inclisiran is an innovative product bringing new benefits to patients with high cholesterol - a major risk factor for cardiovascular disease. The drug has received over 90 regulatory approvals and is marketed globally.
- NovartiscoreBXLS founded Anthos Therapeutics, Inc. in collaboration with Novartis to advance next-generation targeted therapies for high-risk cardiovascular patients. Anthos was sold back to Novartis in April 2025. Investment funded potential next-generation antithrombotic therapies for patients underserved by conventional medicines.
Scale indicators6 records
Recent moves5 records
Expansion highlights5 records
Clarus Ventures competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key risks1 record
Key highlights7 records
Customer concentration
Clarus Ventures social profiles
Digital presenceClarus Ventures financial estimates
Financial estimateRevenue estimate
Valuation estimate
Clarus Ventures leadership team
Management profileNumber of profiles
Profiles6 records
Clarus Ventures funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Clarus Ventures M&A and investment
M&A and investmentM&A
Investments89 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Clarus Ventures
What does Clarus Ventures do?
Clarus Ventures, now operating as Blackstone Life Sciences (BXLS), is a life sciences-focused private equity firm that designs, funds and executes late-stage clinical trials for pharmaceutical, biotech and medical technology products. The firm provides development capital, royalty interest acquisitions, and operational expertise to advance innovative core products through clinical development and regulatory approval.
Is Clarus Ventures a public or private company?
Clarus Ventures is a private company. It is classified as corporate owned and is currently acquired.
When was Clarus Ventures founded?
Clarus Ventures was founded in 2008. It employs 51 to 100 people.
Where is Clarus Ventures based?
Clarus Ventures is headquartered in Cambridge, United States, in the North America region.
How does Clarus Ventures make money?
Three revenue lines are on record. Development Investment Returns are the primary driver. The others are royalty Interests and equity Investments.
Does Clarus Ventures have an API?
No public API is recorded for Clarus Ventures.
What industry is Clarus Ventures in?
Clarus Ventures's product category is Life Sciences Private Equity. Its primary akta.pro industry code is FSANACAD, Business Services (B2B) Growth Equity. Its NAICS code is 523940 and its SIC code is 6282.